12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

OncoVEX GM-CSF: Completed Phase III enrollment

Amgen completed enrollment of 430 patients with stage III-IV melanoma in the open-label Phase III OPTiM trial evaluating intratumoral OncoVEX GM-CSF vs. subcutaneous GM-CSF. Amgen has an SPA from FDA for...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >